749922-34-7

Usage

Uses

Used in Pharmaceutical Industry:
7-Benzyloxy-4-hydroxy-quinoline is used as a key intermediate in the synthesis of various pharmaceuticals and biologically active compounds. Its unique structure and properties contribute to the development of new drugs with potential therapeutic applications.
Used in Antimalarial Applications:
7-Benzyloxy-4-hydroxy-quinoline is used as an antimalarial agent, showing promise in the treatment of malaria. Its ability to target and inhibit the growth of Plasmodium parasites makes it a potential candidate for further research and development in this area.
Used in Antibacterial Applications:
7-Benzyloxy-4-hydroxy-quinoline is used as an antibacterial agent, demonstrating potential in combating bacterial infections. Its ability to disrupt bacterial cell functions and inhibit their growth makes it a valuable compound for the development of new antibiotics.
Used in Antioxidant Applications:
7-Benzyloxy-4-hydroxy-quinoline is used as an antioxidant, exhibiting potential in protecting cells from oxidative stress and damage. Its ability to neutralize free radicals and reduce oxidative stress makes it a promising candidate for the development of antioxidant therapies.
Used in Anti-inflammatory Applications:
7-Benzyloxy-4-hydroxy-quinoline is used as an anti-inflammatory agent, showing potential in reducing inflammation and alleviating symptoms associated with inflammatory conditions. Its ability to modulate inflammatory pathways and reduce the production of pro-inflammatory mediators makes it a valuable compound for the development of anti-inflammatory treatments.

Upstream product

• 909345-85-3 5-((3-(benzyloxy)phenylamino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 1484-26-0 3-(benzyloxy)aniline 
• 749922-33-6 5-{[(3-benzyloxy)phenylimino]methyl}-2,2-dimethyl-[1,3]-dioxane-4,6-dione 

Downstream Products

• 749922-35-8 7-(benzyloxy)-3-nitroquinolin-4-ol 
• 1221443-46-4 N-(3-fluoro-4-(7-hydroxyquinolin-4-yloxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394820-97-3 7-benzyloxy-4-(2-fluoro-4-nitrophenoxy)quinoline 
• 1394820-98-4 4-(2-fluoro-4-nitrophenoxy)quinolin-7-ol 
• 1394820-99-5 1-((4-(2-fluoro-4-nitrophenoxy)quinolin-7-yl)oxy)-2-methylpropan-2-ol 
• 1394820-70-2 (R)-N-(3-fluoro-4-((7-(2-hydroxypropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394821-01-2 4-(4-amino-2-fluorophenoxy)quinolin-7-ol 
• 1394820-83-7 N-(4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394821-02-3 7-(benzyloxy)-4-(4-nitrophenoxy)quinoline 
• 1394821-03-4 4-(4-nitrophenoxy)quinolin-7-ol 
• 1394821-04-5 2-methyl-1-((4-(4-nitrophenoxy)quinolin-7-yl)oxy)propan-2-ol 
• 1394821-05-6 1-((4-(4-aminophenoxy)quinolin-7-yl)oxy)-2-methylpropan-2-ol 
• 1394820-85-9 N-(4-((7-(2-hydroxyethoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394821-06-7 2-((4-(4-nitrophenoxy)quinolin-7-yl)oxy)ethanol 

Relevant academic research and scientific papers

7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD)

7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-l-antitrypsin modulators for treating alpha-l-antitrypsin deficiency (AATD).

Preparation method of quinoline compound

The present invention relates to a preparation method of a quinoline compound, the quinoline compound has a structure represented by a formula (I), and the preparation method comprises the following steps: providing a compound having a structure represented by a formula (I-1); and reacting the compound with the structure shown in the formula (I-1) with 3, 4-difluoro-nitrobenzene to prepare the quinoline compound with the structure shown in the formula (I). The preparation method of the quinoline compound is high in production safety, low in cost and suitable for large-scale industrial production.

Quinoline derivatives (by machine translation)

A compound represented by general formula (I) (I) has a strong Axl inhibiting activity by introducing a distinctive bicyclic structure in which a saturated carbocyclic ring is fused to a pyridone ring, and thus may be used as a therapeutic agent for Axl related diseases such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, cancer such as glioma, kidney disease, immune system disease, and circulatory system disease.

BMP INHIBITORS AND METHODS OF USE THEREOF

The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.

SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Methods , composition and preparations for delivery of immune response modifiers

A soluble IRM-polymer complex, preparations thereof, and methods of use, wherein the soluble IRM-polymer complex includes one or more IRM compounds attached (e.g., covalently attached) to a polymer (e.g., an alkylene oxide-containing polymer).

COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGF2 inhibitory activity.

SUBSTITUTED FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS

Fused [1,2]imidazo[4,5-c] ring compounds, e.g., fused [1,2]imidazo[4,5-c]quinolines and [1,2]imidazo[4,5-c]naphthyridines, with a substituent, e.g., a substituted alkoxy substituent, at the 6, 7, 8, or 9-position, pharmaceutical compositions containing th

CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS

Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a -CH(-X1-R1)-group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES

Thiazoloquinolines and thiazolonaphthyridines with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.